Webcast: Portfolio analysis - Go/No-go decisions
When a pharma company is either considering acquiring a new agent, or developing one in-house, marketers need to understand the impact on the overall portfolio and decide whether to make a go or no-go decision on that asset. Watch this webcast in which Research Partnership's Pei Li Teh and Callum McCulloch (who are both from our Singapore office) discuss how market research insights allow you to make confident go/no-go decisions in portfolio planning.
Webcast: Portfolio analysis - Tracking for success
Portfolio Analysis and Optimization looks at how honing strategy across multiple agents in the same therapeutic category leads to marketing success. As pharmaceutical companies simultaneously develop and in-license multiple products that can cost millions of dollars, portfolio management is about selecting how to allocate resources and marketing efforts across multiple assets. This has significant impact on the bottom line.
Webcast: Portfolio analysis - Choosing your communication strategy
Portfolio Analysis and Optimization concentrates on determining the impact that multiple assets have within therapeutic categories, and how the marketing of these assets impacts on overall strategy. This is an important tool for pharmaceutical companies in today’s market. As they simultaneously develop multiple products that can become extremely costly, portfolio management to improve decision-making can have a significant impact on the bottom line. At its very core, it is about selecting how to allocate resources and marketing efforts across multiple assets.
Webcast: China in the Fast Lane - How to play and win in the world's hottest emerging market
Watch this webcast in which Pei Li Teh and Wan Ling Neo explore China's evolving healthcare environment. In this webcast they highlight the key changes affecting pharma and demonstrate how to build the market understanding required to launch a brand effectively in this exciting region.
Navigating new frontiers: Ways to find space in the future RA market
In partnership with pharmaphorum
Rheumatoid arthritis (RA) has been a major growth driver for the pharmaceutical industry over the last 15 years, led by AbbVie’s blockbuster anti-TNF inhibitor treatment Humira (adalimumab).